Physician profile
Lian Mack
NPI 1083878623
$27,938.98
in general payments reported to CMS, 2019-2025
34 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $301 · 2021: $10K · 2022: $12K · 2023: $1,406 · 2024: $937 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,645 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.55 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $19,275.78 | 2019-2025 | Dysport |
| Abbvie INC. | $1,532.49 | 2019-2025 | |
| Allergan, INC. | $714.03 | 2019-2022 | |
| Amgen INC. | $594.43 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $563.88 | 2019-2025 | Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $555.43 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Lilly USA, LLC | $481.10 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Janssen Biotech, INC. | $454.28 | 2021-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $425.40 | 2019-2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $424.25 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $324.22 | 2019-2025 | |
| Genzyme Corporation | $294.44 | 2021-2025 | |
| Journey Medical Corporation | $263.22 | 2019-2025 | |
| Pfizer INC. | $230.45 | 2019-2023 | |
| Celgene Corporation | $225.96 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $205.36 | 2019-2023 | Xeomin |
| Incyte Corporation | $203.35 | 2021-2025 | Opzelura |
| Almirall LLC | $176.05 | 2020-2023 | Seysara |
| Regeneron Healthcare Solutions, INC. | $167.07 | 2019-2025 | Libtayo, Dupixent |
| Vyne Pharmaceuticals INC. | $115.25 | 2020-2021 | |
| Epi Health, LLC | $91.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.07 | 2022-2024 | Sotyktu |
| Solta Medical, A Division of Bausch Health US, LLC | $81.69 | 2019-2024 | Clear+Brilliant |
| Dermira, INC. | $72.03 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $70.41 | 2019 | |
| Arcutis Biotherapeutics, INC. | $67.43 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $57.24 | 2022-2023 | Vtama |
| Ucb, INC. | $52.82 | 2021 | |
| Encore Dermatology INC. | $34.21 | 2019 | |
| Botanix Sb INC | $24.02 | 2025 | Sofdra |
| Promius Pharma LLC | $23.18 | 2019 | |
| Biofrontera INC. | $19.62 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Horizon Therapeutics Plc | $19.50 | 2019 | |
| Aclaris Therapeutics, INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lian Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.